PT - JOURNAL ARTICLE AU - Mortier, Alexandre AU - Khoudary, Jina AU - van Doorslaer de Ten Ryen, Sophie AU - Lannoy, Camille AU - Benoit, Nicolas AU - Antoine, Nancy AU - Copine, Sylvie AU - Van Remoortel, Hans AU - Vandekerckhove, Philippe AU - Compernolle, Veerle AU - Deldicque, Louise TI - Effects of plasmapheresis frequency on health status and exercise performance in men: a randomized controlled trial AID - 10.1101/2023.06.05.23290943 DP - 2023 Jan 01 TA - medRxiv PG - 2023.06.05.23290943 4099 - http://medrxiv.org/content/early/2023/06/05/2023.06.05.23290943.short 4100 - http://medrxiv.org/content/early/2023/06/05/2023.06.05.23290943.full AB - Objectives To collect data on 1) haematological and biochemical markers, 2) physiological and exercise-related parameters and 3) adverse events to get a comprehensive picture of the safety of intensive or less intensive plasma donation protocols.Methods Sixty-three male subjects participated in this randomized controlled trial and were divided into a low-frequency (LF, 1x/month, n=16), high-frequency (HF, 3x/month, n=16), very high-frequency (VHF, 2x/week, n=16) and a placebo (P, 1x/month, n=15) group. Biochemical, haematological, clinical, physiological and sport performance-related data were collected before (D0), after 1½ month (D42) and after 3 months (D84).Results In VHF, red blood cells, haemoglobin and haematocrit levels decreased while reticulocyte levels increased from D0 to D84. In both HF and VHF, plasma ferritin levels were lower at D42 and D84 compared to D0. In VHF, the plasma levels of albumin, IgG, IgA and IgM dropped from D0 to D42 and remained lower at D84 than at D0. In HF, plasma IgG, IgA and IgM were lower at D42 and IgG and IgM were lower at D84 compared to D0. Few adverse events (haematoma, anaemia, vasovagal reactions without syncope) were reported in HF and VHF. Repeated plasma donation had no effect on blood pressure, body composition or exercise performance.Conclusion Haematological and biochemical parameters were severely impacted when plasmapheresis was repeated twice a week, mildly impacted with a frequency of three times per month and not impacted with a frequency of once a month. Despite those changes, markers for exercise performance were not altered when plasmapheresis, whatever the frequency, was repeated over 3 months.What is already known on this topic?Plasmapheresis may induce a series of health consequences, such as adverse events of diverse severities. However, those events have mainly been studied separately and retrospectively with no appropriate placebo group.What this study adds?This is the first randomized controlled trial prospectively investigating the effects of repeated plasma donation on a whole range of health consequences, namely biochemical and haematological, blood pressure, body composition, adverse events and, exercise performance.How this study might affect research, practice or policy?Worldwide efforts need to be made to increase the amount of plasma collected for manufacturing plasma-derived product. To avoid negative effects to donors, a sustainable plasma supply should be based on a large donorbase of low-frequency donors.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05815615Clinical Protocols https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000D0C3&selectaction=Edit&uid=U00069FK&ts=2&cx=-br52hk Funding StatementThe study was funded by the Science Foundation of the Belgian Red Cross.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of UCLouvain and the investigation was performed according to the principles outlined in the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors